Literature DB >> 16630235

Posterior pelvic exenteration for primary rectal cancer.

G C Bannura1, A E Barrera, M A G Cumsille, J P Contreras, C L Melo, D C Soto, J E Mansilla.   

Abstract

BACKGROUND: Indications for and the prognosis of posterior pelvic exenteration (PPE) in rectal cancer patients are not clearly defined. The aim of this study was to analyse the indications, complications and long-term results of PPE in patients with primary rectal cancer.
METHODS: A retrospective review included patient demographics, tumour and treatment variables, and morbidity, recurrence, and survival statistics. These results were compared with a group of female patients who underwent standard resection for primary rectal cancer in the same period (non PPE group).
RESULTS: The series included 30 women with an average age of 56.7 years (range 22-78). Tumour location was recorded in three cases in the upper rectum, 13 cases in the medium rectum and 14 cases in the lower rectum. A sphincter-preserving procedure was performed in 70% of the patients. Mean operative time was 4.2 h (range 2-7.5 h). Overall major morbidity rate in this series was 50% and mean hospital stay was 19.7 days (range 9-60 days). There was no hospital mortality. Pathological reports showed direct invasion of uterus, vagina or rectovaginal septum in 19 cases, involvement of perirectal tissue in 25 cases and positive lymph nodes in 18 cases. Comparison between PPE and non PPE groups showed no differences in mean tumour diameter, histological grade and tumour stage, but patients in the first group were younger. Although low tumours were seen more frequently in the PPE group (P = 0.003), the rate of sphincter-preserving procedure was comparable in both groups. Operative time was longer (P = 0.04) and morbidity was higher (P = 0.0058) in the PPE group. Local recurrence with or without distant metastases for the whole series was 30%. Five-year survival rate for patients who underwent curative resections (TNM I-III) was 48% in the PPE group vs 62% in the non PPE group (P = 0.09).
CONCLUSIONS: In the present series, PPE prolonged operative time, increased postoperative complications and showed a trend toward poor prognosis in recurrence and survival. However, PPE offers the only hope for cure to patients with a primary rectal cancer that is adherent or invades reproductive organs.

Entities:  

Mesh:

Year:  2006        PMID: 16630235     DOI: 10.1111/j.1463-1318.2005.00938.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies.

Authors:  Rajaraman Ramamurthy; Amudhan Duraipandian
Journal:  Indian J Surg Oncol       Date:  2012-07-18

2.  Pelvic Exenteration Put into Therapeutical and Palliative Perspective: It Is Worth to Try.

Authors:  Iosifina Karmaniolou; Nikolaos Arkadopoulos; Pantelis Vassiliou; Constantinos Nastos; Dionysios Dellaportas; Argyris Siatelis; Theodosis Theodosopoulos; Antonios Vezakis; Stavros Parasyris; Andreas Polydorou; Vassilios Smyrniotis
Journal:  Indian J Surg Oncol       Date:  2018-07-20

3.  Comparison of immediate surgical outcomes between posterior pelvic exenteration and standard resection for primary rectal cancer: a matched case-control study.

Authors:  Varut Lohsiriwat; Darin Lohsiriwat
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

4.  Selection criteria for the radical treatment of locally advanced rectal cancer.

Authors:  Mansel Leigh Davies; Dean Harris; Mark Davies; Malcolm Lucas; Peter Drew; John Beynon
Journal:  Int J Surg Oncol       Date:  2011-10-13

Review 5.  Rectal cancer: a review.

Authors:  Mohammad Sadegh Fazeli; Mohammad Reza Keramati
Journal:  Med J Islam Repub Iran       Date:  2015-01-31

6.  Efficacy of an additional flap operation in bladder-preserving surgery with radical prostatectomy and cystourethral anastomosis for rectal cancer involving the prostate.

Authors:  Keita Noguchi; Yuji Nishizawa; Yoshinobu Komai; Yasuyuki Sakai; Akihiro Kobayasi; Masaaki Ito; Norio Saito
Journal:  Surg Today       Date:  2017-03-04       Impact factor: 2.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.